Oligonucleotide CDMO Market

The oligonucleotide CDMO market is projected to reach USD 11.14 billion by 2031 from USD 3.88 billion in 2026, at a CAGR of 23.5% during the forecast period.

Agilent Technologies, Inc. (US), Bachem (Switzerland), WuXi AppTec, Thermo Fisher Scientific Inc. (US), and ST Pharm (South Korea) are the key players in this market.

These market players have adopted various strategies, including service innovations, collaborations, acquisitions, agreements, and expansions, to strengthen their market positions. In April 2026, Bachem inaugurated Building K in Bubendorf, an industrial-scale facility designed to meet growing demand for peptide and oligonucleotide APIs. The facility strengthens Bachem's large-scale manufacturing capabilities.

In March 2026, Agilent launched Agilent Advanced Therapeutics, a unified CDMO solution that combines BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado. The platform covers oligonucleotides and offers services from discovery and process development through clinical- and commercial-scale manufacturing, strengthening Agilent's end-to-end oligo CDMO offering.

Agilent Technologies (US): Agilent Technologies holds a leading position in the oligonucleotide CDMO market, supported by its established GMP manufacturing infrastructure and broad scale-up capabilities. The company supports oligonucleotide programs from preclinical development through commercial manufacturing. Its Boulder facilities provide small-, mid-, and large-scale production, with capabilities spanning grams to tens of kilograms. Agilent also has experience supporting commercially approved oligonucleotide therapeutics. Its integrated capabilities across synthesis, purification, analytical testing, and quality control enable customers to maintain process continuity across development stages.

Bachem (Switzerland): Bachem supports oligonucleotide programs from preclinical development through commercial supply and provides services spanning process development, synthesis, purification, analytical testing, and regulatory support. Bachem offers scalable production across small-, medium-, and large-scale GMP manufacturing. Its capabilities span ASOs, siRNA, and conjugated oligonucleotides. The company also benefits from established expertise in complex molecules and a strong quality and regulatory framework. Its end-to-end model and scalable manufacturing infrastructure strengthen its position as a leading oligonucleotide CDMO.

WuXi AppTec (China): WuXi AppTec is a leading oligonucleotide CDMO through its WuXi TIDES platform, which provides integrated services spanning discovery, process development, and clinical and commercial manufacturing. Its capabilities span ASOs, siRNA, PMOs, sgRNA, conjugates, and modified oligonucleotides. The company operates approximately 30 oligonucleotide manufacturing lines across multiple scales and integrates manufacturing with analytical and regulatory CMC support. Its broad modality coverage, large manufacturing capacity, and integrated CRDMO model strengthen its market position.

Market Ranking

The oligonucleotide CDMO market is consolidated, with leading specialized CDMOs and life science companies strengthening their positions through manufacturing capacity and integrated service offerings. Key players include Agilent Technologies, Inc. (US), Bachem (Switzerland), WuXi AppTec, Thermo Fisher Scientific Inc. (US), and ST Pharm (South Korea). Agilent supports oligonucleotide development and GMP manufacturing across clinical and commercial stages. Bachem provides integrated CMC services from process development through commercial production. WuXi AppTec offers end-to-end oligonucleotide services covering discovery, process development, analytical testing, and commercial manufacturing across multiple oligonucleotide modalities. ST Pharm strengthens the market through integrated monomer and oligonucleotide manufacturing, with capabilities extending to large-scale production. Thermo Fisher Scientific contributes through its broad CDMO infrastructure and oligonucleotide development and manufacturing capabilities. Collectively, these companies support the market through scalable synthesis, purification, analytical development, GMP manufacturing, and commercial supply capabilities.

Related Reports:

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]